Details of the Drug

General Information of Drug (ID: DMJUVE6)

Drug Name
Bulevirtide
Synonyms Lipopeptide
Indication
Disease Entry ICD 11 Status REF
Hepatitis D virus infection 1E51.2 Approved [1]
ATC Code
J05AX28: Bulevirtide
J05AX: Other antivirals
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Peptide
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 351 +/- 72 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 6.13 +/- 1.29 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 8.4 +/- 3.6 h [2]
Bioavailability
The bioavailability of drug is 64-90% [2]
Clearance
The clearance of drug is 7.98 L/h [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 7 hours [4]
Metabolism
The drug is metabolized via peptidases to smaller peptides and amino acids [3]
Cross-matching ID
PubChem CID
134687648
UNII
WKM56H3TLB
DrugBank ID
DB15248
TTD ID
D2G4HB

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/bile acid cotransporter (SLC10A1) TTWZRY5 NTCP_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03852719) Phase 3 Study of Bulevirtide in Patients With CHD. U.S. National Institutes of Health.
2 FDA Approved Drug Products: Conjupri Levamlodipine Oral Tablets
3 EMA Public Assessment Report: Hepcludex (bulevirtide) powder for injectable solution
4 EMA Summary of Product Characteristics: Bulevirtide
5 Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605.